Palatin Technologies, Inc.
PTN · Price history
Price at last available close
$4.77
−$4.81 (-50.21%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Palatin Technologies, Inc.
Primary reporting period: 2026-06-30 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases.
How they make money
Palatin Technologies is a biopharmaceutical company that focuses on the development of targeted, receptor-specific therapeutics based on the melanocortin receptor system. The company's business model relies on developing product candidates through clinical trials and subsequently entering into licensing or marketing collaborations with industry partners to commercialize these assets and generate revenue through milestone payments and royalties.
Products & services
The company develops melanocortin receptor-targeted therapeutics, including Vyleesi for HSDD, PL9643 for dry eye disease, and bremelanotide combinations for erectile dysfunction.
Brands & revenue mix
An FDA-approved melanocortin agent for the treatment of hypoactive sexual desire disorder in premenopausal women.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Pharmaceutical and biotechnology industry partnersSource
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) — The company utilizes various unnamed third-party contract research organizations to conduct clinical trials and preclinical studies.Source
- Contract Manufacturing Organizations (CMOs) — The company relies on unnamed third-party contract manufacturers for the production of drug substances and drug products for clinical and commercial use.Source
Business relationships & partnerships
- Boehringer Ingelheim International GmbH — A licensing and acquisition agreement where Boehringer Ingelheim acquired certain Palatin patent applications related to melanocortin receptor-targeted peptides for retinal diseases and glaucoma.Source
Strengths
- Proprietary expertise in the melanocortin receptor systemSource
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
29
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
41
Weak
Financial Strength
64
Business Quality / Moat
25
Management
60
Growth Quality
27
Risk / Durability
0
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
34
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
44/100
Building Historical Record
Model Score 44/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Material dilution — approximately 425.2% share-count growth
- •Debt service risk
- •M&A headline · Aug 6, 2026
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
Company-specific research
Questions worth answering for PTN
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can PTN maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can PTN fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is PTN likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for PTN to reach sustainable profitability?
- •What future growth or profitability would be needed to justify PTN's current valuation?
Essential Investment Snapshot
Wall Street Score
29
Opportunity Score
34
Market Cap
$8.5M
P/E Ratio
-1.4
EPS
$-5.25
52-Week High
$31.00
52-Week Low
$5.61
Beta
-0.07
Analyst Target
$47.50
Shares Outstanding
2.8M
Total Revenue
$13.2M
Total Debt
$224K
Dividend
No current dividend
Liquidation Value / Share
$2.37
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Elevated movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for PTN
Detected from reported data — verify before acting.Material dilution — approximately 425.2% share-count growth
Diluted shares outstanding grew ~425.2% year-over-year. Substantial dilution reduces per-share value and can signal financing stress. Wall Street Score is capped.
Debt service risk
Interest coverage is low (~-1288.8x). Earnings may be strained to cover interest expense.
M&A headline · Aug 6, 2026
StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Newsfile CorpCommunity Sentiment
0 active · 0 total callsNo personal call yet on PTN.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary expertise in the melanocortin receptor system.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Dependence on third-party manufacturers and clinical research organizations.
- −History of operating losses and need for additional capital.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
29
Oct 1, 2026
Change
+0.6
points
Current Score
29
Oct 15, 2026
Category Changes
PTN increased 0.6 points because Asset improved by 3.5 points.
Positive Contributors
- + Asset improved by 3.5 points
Projected Score
Projected Score
31
Projected Change
+1.2 points
Preliminary comparable-period financial changes suggest improvement of approximately 1.2 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$4.77
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: +193.6%
Revenue changed sharply from 2024 to 2026. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.2M | $13.2M | $0.00 | $4.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $63K | $63K | $0.00 | $98K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $13.1M | $13.1M | $0.00 | $4.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $12.4M | $12.4M | $14.9M | $22.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $9.5M | $9.5M | $7.8M | $12.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $21.9M | $21.9M | $17.5M | $26.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$8.6M | -$8.6M | -$17.0M | -$29.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$8.7M | -$8.7M | -$17.5M | -$22.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $7K | $7K | $15K | $17K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$8.4M | -$8.4M | -$17.3M | -$29.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$8.4M | -$8.4M | -$17.3M | -$29.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-2.96 | $-2.96 | $-32.15 | $-2.02 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 3.92M | 2.83M | 538K | 14.70M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 3.92M | 2.83M | 538K | 14.70M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$300770
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$1.11
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+36.6%
Cash Change
+192.2%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
What Weakened
- Debt increased
Potential Score Impact
Positive indicators included EPS growth, cash levels. Pressure indicators included debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS increased 117.6%. Cash increased 192.2%. Total debt increased 36.6%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
What Palatin Technologies (PTN) Said on Its Q4 Earnings Call
Palatin Technologies, Inc. (PTN) Q4 2026 Earnings Call Transcript
Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update
Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update
Rumor Mill · PTN
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial